[Funding alert] Copenhagen-based Hedia Secures €3Million in Seed Extension Funding

The business plans to utilise the money to build up their Hedia Diabetes Assistant (HDA), introduce the Glooko integrated holistic diabetes care solution later in the year, and broaden its growth strategy and digital health product pipeline.

Read also - London-based KLIQ Secures €1.4 Million in Pre-Seed Funding

Additionally, it will work with strategic partners to develop Software-as-a-Medical Device (SaMD) solutions and intelligent AI-enabled algorithms related to chronic metabolic illnesses.

It is a digital therapeutics firm focused on helping patients with insulin-dependent diabetes take control of their illness. It is led by Lars Lund, the recently appointed CEO.

Right now, eleven nations have access to the solution. Its diabetes app generates insulin recommendations based on the specific habits of the person with diabetes and personalised input. It considers various aspects of diabetes management, including measuring carbohydrates, recording blood glucose levels, monitoring active insulin, keeping track of activity, and measuring blood ketones.

Read also - Manchester-based ESProfiler Secures £2.8 Million in Seed Funding

About Hedia

Hedia's mission is to enhance the lives of those who have diabetes by providing the greatest diabetes management resources to as many individuals as possible. The goal of the class IIb medical device Hedia Diabetes Assistant (HDA) is to assist in better managing diabetes that requires insulin and, as a result, promote desired health outcomes including blood glucose stability.